Share

August 30, 2016; 87 (9 Supplement 2) Article

Consensus definitions for pediatric MS and other demyelinating disorders in childhood

Marc Tardieu, Brenda Banwell, Jerry S. Wolinsky, Daniela Pohl, Lauren B. Krupp
First published August 29, 2016, DOI: https://doi.org/10.1212/WNL.0000000000002877
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
4336

Share

Article Information

vol. 87 no. 9 Supplement 2 S8-S11
DOI: 
https://doi.org/10.1212/WNL.0000000000002877
PubMed: 
27572866
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received August 19, 2015
  • Accepted in final form March 1, 2016
  • First Published August 29, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Marc Tardieu, MD, PhD,
    2. Brenda Banwell, MD,
    3. Jerry S. Wolinsky, MD,
    4. Daniela Pohl, MD, PhD and
    5. Lauren B. Krupp, MD
  1. Marc Tardieu, MD, PhD,
    2. Scientific Advisory Boards:

    1. 1. Scientific advisory board for Biogen, Genzyme and Novartis for new treatment in pediatric MS.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Multiple sclerosis Journal

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Brenda Banwell, MD,
    3. Scientific Advisory Boards:

    1. Scientific Advisory Board, Biogen-IDEC, Sanofi, Eli Lilly, Novartis.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. I have received speaker's honoraria or travel support to speak at sponsored meetings from Biogen-IDEC, Merck- Serono, Teva Neuroscience and Bayer. I have not received this for more than 2 years.

    Editorial Boards:

    1. I serve on the Editorial Board for Neurology. I receive no financial remuneration. I also serve on the Editorial Board for a new journal, Multiple Sclerosis and Related Disorders. I receive compensation for this work .

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. I have served as a consultant to Biogen-IDEC, Eli Lilly, Sanofi.

    Speakers' Bureaus:

    1. I have spoken at an event supported by the Consortium of MS Centers

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Multiple Sclerosis Society of Canada Multiple Sclerosis Scientific Research Foundation National Multiple Sclerosis Society

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Jerry S. Wolinsky, MD,
    4. Scientific Advisory Boards:

    1. Compensation for service on steering committees or data monitoring boards for Forward Pharma, Novartis Pharmaceuticals, Roche/Genentech, and Sanofi/Genzyme.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Honoraria were provided from ACTRIMS, AcademicCME, WebMD, and the University of Kansas for CME activities. (2) Travel support was provided from ECTRIMS as invited faculty to the Barcelona meeting, and ACTRIMS as Keynote Speaker for the New Orleans meeting.

    Editorial Boards:

    1. (1) Multiple Sclerosis Journal, Sage, Editorial Board, 1994 - present (2) Multiple Sclerosis and Related Diseases, Elsevier, Section Editor, 2011 - present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Reimbursement for services as consultant to AbbVie, Acetilon, Alkermes, Forward Pharma, EMD Serono, Genzyme, Novartis, Roche, Taketa, Teva, and XenoPort.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Genzyme (2) Teva

    Research Support, Government Entities:

    1. (1) National Institutes of Health, 2 U01 NS045719-07 (PI of the subcontract to UTHSCH for image analysis), 2002 - 2015 (2) National Institutes of Health, NS078244-01A1 (Co- investigator), 2012 - 2017

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License fee payments, Technology or Inventions:

    1. (1) Royalties are received for monoclonal antibodies out-licensed through the University of Texas Health Science Center at Houston to Millipore (Chemicon International) Corporation since 1993.

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Daniela Pohl, MD, PhD and
    5. Scientific Advisory Boards:

    1. (1) Biogen-Idec (2) Novartis (3) Sanofi (4) Merck-Serono

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) EAN: Funding for travel (2) LACTRIMS: Funding for travel

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Lauren B. Krupp, MD
    6. Scientific Advisory Boards:

    1. Dr. Krupp has served on the scientific advisory boards for Acorda , Genentech, Pfizer, Sanofi-Aventis, Novartis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Dr. Krupp served on the speakers? bureau for Bayer, Biogen Idec, TevaNeuroscience, EMD-Serono, National MS Society

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Dr. Krupp is a consultant for Gerson Lehrman Group; Guidepoint Global; Axon Advisors

    Speakers' Bureaus:

    1. Dr. Krupp served on the speakers? bureau for Bayer, Biogen Idec, TevaNeuroscience, EMD-Serono and Multiple Sclerosis Association of America

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Dr. Krupp has received research support from Biogen Idec, EMD-Serono, TevaNeurosciences, Novartis, Genentech, Celgene Corporation, Garnett McKeen Laboratory Incorporated

    Research Support, Government Entities:

    1. National Institutes of Health (grant 2 R01 HD38107) PI 2004-2008

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Dr. Krupp has received research support from National Multiple Sclerosis Society (NMSS), Lourie Foundation, Slomo and Cindy Silvian Foundation, Multiple Sclerosis (MS) Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the National Reference Center for Inflammatory Diseases of the Brain (M.T.), Hôpitaux Universitaires Paris-Sud, University Paris-Sud, France; Perelman School of Medicine (B.B.), The Children's Hospital of Philadelphia, University of Pennsylvania; University of Texas Health Science Center at Houston (J.W.); Department of Neurology (D.P.), Children's Hospital of Eastern Ontario, University of Ottawa, Canada; and Lourie Center for Pediatric MS (L.B.K.), Stony Brook Children's, NY.
  1. Correspondence to Dr. Tardieu: marc.tardieu{at}bct.aphp.fr
View Full Text

Article usage

Article usage: August 2016 to May 2023

AbstractFullPdfSource
Aug 20163662698Highwire
Sep 20161057130282Highwire
Oct 201637568154Highwire
Nov 20162244980Highwire
Dec 20161563262Highwire
Jan 20171854870Highwire
Feb 20171894567Highwire
Mar 20171633665Highwire
Apr 20171521655Highwire
May 20171493859Highwire
Jun 20171274359Highwire
Jul 20171283162Highwire
Aug 20171002865Highwire
Sep 20171293066Highwire
Oct 2017983046Highwire
Nov 2017784755Highwire
Dec 201758763Highwire
Jan 2018210478Highwire
Feb 2018211952Highwire
Mar 201848867Highwire
Apr 201829658Highwire
May 2018211356Highwire
Jun 201838261Highwire
Jul 201858375Highwire
Aug 201828641Highwire
Sep 2018610358Highwire
Oct 2018109058Highwire
Nov 2018510349Highwire
Dec 201817926Highwire
Jan 20191510678Highwire
Feb 2019228256Highwire
Mar 2019197670Highwire
Apr 2019165053Highwire
May 2019224537Highwire
Jun 2019134654Highwire
Jul 2019335650Highwire
Aug 2019184938Highwire
Sep 2019135252Highwire
Oct 2019216454Highwire
Nov 2019274442Highwire
Dec 2019143264Highwire
Jan 2020224972Highwire
Feb 2020113469Highwire
Mar 202073039Highwire
Apr 2020134637Highwire
May 2020263774Highwire
Jun 202093952Highwire
Jul 2020103552Highwire
Aug 202072732Highwire
Sep 2020253245Highwire
Oct 2020233445Highwire
Nov 2020225468Highwire
Dec 2020264160Highwire
Jan 2021172540Highwire
Feb 2021122433Highwire
Mar 2021164642Highwire
Apr 2021235332Highwire
May 2021234964Highwire
Jun 202182230Highwire
Jul 2021143731Highwire
Aug 2021172830Highwire
Sep 2021272848Highwire
Oct 2021372953Highwire
Nov 202173551Highwire
Dec 2021124834Highwire
Jan 2022232630Highwire
Feb 2022142936Highwire
Mar 2022224133Highwire
Apr 2022254731Highwire
May 2022194141Highwire
Jun 2022162844Highwire
Jul 2022151720Highwire
Aug 2022102222Highwire
Sep 20222011320Highwire
Oct 2022154121Highwire
Nov 202292831Highwire
Dec 2022192516Highwire
Jan 2023133619Highwire
Feb 202394118Highwire
Mar 2023165119Highwire
Apr 2023104038Highwire
May 2023231829Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles